Vaccibody.com | VACCIBODY AS ANNOUNCES INFORMED CONSENT SIGNED BY FIRST PATIENT AND ENROLMENT PROCESS INITIATED IN THE CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL.
1323
post-template-default,single,single-post,postid-1323,single-format-standard,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-13.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive

VACCIBODY AS ANNOUNCES INFORMED CONSENT SIGNED BY FIRST PATIENT AND ENROLMENT PROCESS INITIATED IN THE CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL.

Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces informed consent signed by the first patient and enrolment process initiated in the clinical trial. The patient will be enrolled in Heidelberg, Germany at the National Center for Tumor Diseases by principal investigator, Prof. Dr. med. Jürgen Krauss, Head of Section for Clinical Immunotherapy.

Prof. Dr. med. Jürgen Krauss, said, “We are very pleased to have initiated this clinical phase I/IIa for Vaccibody’s neoantigen vaccine. The neoantigen vaccine holds the potential to assist the patient’s immune system to generate specific T-cell responses to its individual cancer neoantigens and in this way may help the patient to more effectively fight the cancer. We hope this clinical trial will help pave the way for a novel class of new efficacious and safe treatment for cancer patients.

Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said “We are proud and very pleased to work with so experienced cancer experts in this trial as Prof. Jürgen Krauss from Heidelberg, Prof. Angela Krackhardt from Munich and Prof. Elke Jäger from Frankfurt. This first-in-man trial is planned to enroll up to 40 patients with locally advanced or metastatic non-small cell lung cancer, melanoma, renal, bladder or head and neck cancer. The VB10.NEO vaccine will be given in combination with standard of care checkpoint inhibitors as a new treatment modality to help patients with cancer.

Dr. Agnete Fredriksen, President and Chief Scientific Officer in Vaccibody, commented “The first patient marks an important new phase in Vaccibody and we are very excited to start to tailor-make one vaccine per patient using our proprietary vaccination technology. The unique ability to induce strong CD8 T cell responses to multiple neoepitopes that we have observed in preclinical models, in addition to the manufacturing advantages essential for individualized vaccines, are basis for our enthusiasm moving this concept into clinical trials.

About Vaccibody AS
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. Vaccibody is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which is now fully enrolled, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

Contact:
Martin Bonde CEO
+47 22958193
mbonde@vaccibody.com

SOURCE
Vaccibody AS
Oslo Research Park
Gaustadalléen 21 0349 Oslo, Norway